Undergraduate School

B.S., University of Delhi, 2001

Other School

Ph.D., Cell and Molecular, University of Notre Dame, 2007

Fellowship

Senior Scientist, Abbive Inc., 2012-14

Fellowship

Principal Scientist, Boehringer Ingelheim, 2014-15

Fellowship

Post Doc, Biochemistry and Molecular Genetics, University of Massachusetts Medical School, 2009-2012

Breast Cancer Research Breakthrough award by U.S Department of Defense (DoD) (2017),

Early Career Investigator Award, Ovarian Cancer Academy, U.S. DoD (2018),

Invited Plenary Speaker, Paris “Mobilizing T-cell to tumors, CAR-T and Bispecific Antibodies” (2019) Schiff Foundation award (2020),

Executive Vice President (EVP)'s Exceptional Research Contribution Award Merit List, University of Virginia School of Medicine (2021),

https://pubmed.ncbi.nlm.nih.gov/?term=tushir-singh&sort=date

https://pubmed.ncbi.nlm.nih.gov/?term=tushir-singh&sort=date

 

1. Pirillo E, Freenor VF, Wamba BE, Bhatnagar S, Mondal T, and Tushir-Singh J*. An evolutionary T119R substitution in the macaque T-cell immunoreceptor TIGIT enables proteolytic shedding and reveals clinical antibody vulnerabilities. J Biol Chem. 2025 Nov 20:110962. doi: 10.1016/j.jbc.2025.110962., *Corresponding Author

2. Song Lou, Rachisan DJiake Tihagam , Urszula N Wasko, Zaffar Equbal, Sanjay Venkatesan, Klaudia Braczyk, Piotr Przanowski, Bon Il Koo, Ilyas Saltani, Arjun Tushir Singh, Shibi Likhite, Samantha Powers, George M P R Souza, Robert A Maxwell, Jun Yu, Lihua J Zhu, Mark Beenhakker, Stephen B G Abbott, Zhipeng Lu, Michael R Green, Kathrin C Meyer,  Tushir-Singh J, Sanchita Bhatnagar. Targeting microRNA-dependent control of X chromosome inactivation improves the Rett Syndrome phenotype. Nat Commun. 2025 Jul 4;16(1):6169. doi: 10.1038/s41467-025-61092-7.

3. Wamba BE, Mondal T, Freenor FV, Shaheed M, Pang O, Bedinger D, Legembre P, Devel L, Bhatnagar B, Leiserowitz GS, and Tushir-Singh J*. Evolutionary Regulation of Human FasL by Plasmin in Solid Cancer Immunotherapy. Nat Commun. 2025 Jul 1;16(1):5748. doi: 10.1038/s41467-025-60990-0. *Corresponding Author 

4. Rachisan Gt Tihagam, Lou S ….Tushir-Singh J, et al., A TRIM37 risk variant rs57141087 contributes to triple-negative breast cancer onset and progression in Black women. 2024, EMBO Reports, EMBOR-2024-59512V2: In press.

5. Tanmoy Mondal, Himanshu Gaur, Brice E N Wamba, Abby Grace Michalak, Camryn Stout, Matthew R Watson, Sophia L Aleixo, Arjun Singh, Salvatore Condello, Roland Faller, Gary Scott Leiserowitz, Sanchita Bhatnagar, Tushir-Singh J*. Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer. Cell Death Differ. 2023 Nov;30(11):2408-2431. doi: 10.1038/s41418-023-01229-7. Epub 2023 Oct 14. *Corresponding Author

6. Mondal T, Shivange G, Habieb, A and Tushir-Singh, J*. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Chain of Infection Cycle. (2022) Microbiology Spectrum Feb 23;10(1):e0236421, doi: 10.1128/spectrum.02364-21. Epub 2022 Feb 9. *Corresponding Author

7. Gururaj Shivange, Tanmoy Mondal, Evan Lyerly, Sanchita Bhatnagar, Charles N. Landen, Shivani Reddy, Jonathan Kim, Britney Doan, Paula Riddle and Tushir-Singh, J*. A patch of positively charged residues regulates efficacy of clinical DR5 antibodies in solid tumors. Cell Reports 2021 Nov 2;37(5):109953 Feb 23;10(1):e0236421. *Corresponding Author

8. Lum L.G and Tushir-Singh, J*. Arming “Old Guards” with “New Dual-Targeting Weapons”. Cancer Cell (2021) May 10; 39 (5), 604-606 *Corresponding Author

9. Dhillon P and Tushir-Singh, J, Lum L.G. Bispecific antibodies for the treatment of Breast Cancer, Expert Opinion in Biol Therapy 2021, May 9, 1-11

10. Mondal T, Shivange G, Urbanek K, Rachisan G.T., Batista M, Talwar P, Lyerly E, Mosavian R, Harrell, J. C, Bos, P. Stack S, Bhatnagar S, and Tushir-Singh, J*, Unexpected PD-L1 Immune Evasion by DR5 Agonist Antibodies in Ovarian, TNBC and other Solid Tumors. (2021) EMBO Mol Medicine. Mar 5;13(3):e12716            

11. Przanowski P, Lou S, Mondal T, Djiake R, Conlan C, Shivange G, Saltani I, Xing K, Morris B, Mayo M, Teixeira L, Lehmann-Che J, Tushir-Singh J*, and Bhatnagar S. Oncogenic TRIM37 links chemoresistant and metastatic fate in triple negative breast cancer. Cancer Research (2020) Aug 27:canres.1459.2020. doi: 10.1158/0008-5472.CAN-20-1459 *Corresponding Author

12. Shivange G, Mondal T, and Tushir-Singh J*. Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody. J. Vis. Exp. e60727, (2020) *Corresponding Author

13. Tushir-Singh J*. Targeting HER2 Beyond Breast Cancer. Mol. Cell. Oncology. 2019. Mar 20;6(3):1571984, Invited Commentary. *Corresponding Author

14. Gururaj Shivange, Karol Urbanek, Piotr Przanowski, Justin Perry, James Jones, Robert Haggert, Christina Koska, Edward B. Stelow, Yuliya Petrova, Danielle Llaneza, Marty Mayo, Kodi S. Ravichandaran, Charles N. Landen, Sanchita Bhatnagar, and Tushir-Singh J*. A Single Agent Dual Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. Cancer Cell. 2018 August 13;34(2):331-345.e11

*Corresponding Author

15. Przanowski P, Wasko U, Zheng Z, Yu J, Sherman R, Zhu LJ, McConnell MJ, Tushir-Singh J, Green MR, Bhatnagar S. Pharmacological reactivation of inactive X-linked Mecp2 in cerebral cortical neurons of living mice. PNAS 2018 July 31;115(31):7991-7996

16. Tushir-Singh J, Antibodies-siRNA conjugates: drugging the undruggable for anti-leukemic therapy. Expert Opin Biol Ther. 2017 March 17(3): 325-338. Expert Opinion in Biological Therapy *Corresponding Author

17. Tushir-Singh J and Bhatnagar S. In Vitro Assay to Study Histone Ubiquitination During Transcriptional Regulation. Methods Mol Biol. 2017;1507:235-244 *Corresponding Author

18. Bhatnagar S, Claude G, Chamberlain L, Ou J, Zhu X, Tushir JS, Virbasius CM, Lin L, Zhu LJ, Wajapeyee N and Green MR. TRIM37 is a new histone H2A ubiquitin Ligase and breast cancer oncoprotein. Nature 2014 Dec 4; 516: 116-120. PMID: 25470042 PMCID: PMC4269325.

19. Tushir JS & Akbarian S. Chromatin Bound RNA and Neurobiology of Psychiatric diseases. Neuroscience Journal. 2013 Jul 3:S0306-4522(13)00557-5. Review Article 

20. Bharadwaj R, Jiang Y, Mao W, Mira J, Dincer A, Krueger W, Garbett K, Whittle C, Tushir JS, Liu J, et al; Conserved chromosome 2q31 confirmations are associated with transcriptional regulation of GAD1 GABA synthesis enzyme and altered in prefrontal cortex of subjects with schizophrenia. Journal of Neuroscience 2013 

21. Shulha HP*, Crisci J*, Reshetov D*, Tushir JS*, Cheung I, Bharadwaj R, Chou HJ, Houston I, Peter CJ, Mitchell AC, Yao WD, Myers RH, Chen JF, Preuss TM, Rogaev E#2, Jensen JD#, Weng Z#, Akbarian S# *equal first author Adaptive, Human-specific Gains in Histone Methylation at Transcription Start Sites of Prefrontal Neurons. Submitted: PloS Biology 2012, Nov 10(11):e1001427 *Contributed equally

22. Seitz H*, Tushir, JS* and Zamore, PD. A 5’ Uridine amplifies miRNA/miRNA* asymmetry in Drosophila by promoting RISC formation. Silence (2011) June 7, 2(1) *Contributed equally

23. Tushir, JS Clancy J, Warren A, Wrobel C, Brugge, JS. and D’Souza Schorey, C. Unregulated ARF6 activation in epithelial cysts generates hyperactive signaling endosomes and disrupts epithelial morphogenesis. Mol Biol Cell 2010 July:21(13) 2355-66. Article feature on Journal Cover 

24. Tushir, JS, Zamore PD & Zhang Z. Fly piRNAs, Piwi Proteins and Ping Pong Cycle. Cell 2009 Oct 30;139(3):634, 634.e1 

25. Tushir, JS, Zamore PD & Zhang Z. Mouse piRNAs, Piwi Proteins and Ping Pong Cycle. Cell 2009 Nov 13;139(4):830-830.e1 

26. Tushir, JS and D’Souza-Schorey C (2007) ARF6-dependent activation of ERK and Rac1 modulates epithelial tubule development. EMBO J 2007 Apr 4;26(7):1806-19, 

27. Palacios, F. Tushir, JS*, Fujita, Y and C. D’Souza-Schorey (2005) Lysosomal targeting of E- cadherin: a unique mechanism for the down regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Biol Cell. 25(1): 389-402,